Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

NCT02951637 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Lung Adenocarcinoma

Interventions

DRUG: Pemetrexed plus carboplatin combined with gefitinib
DRUG: Gefitinib

Sponsor

Shanghai Chest Hospital

Collaborators

[object Object]
[object Object]